Replies to post #162166 on Biotech Values

[dav1234]

UBS likes the risk/reward profile for Momenta Pharmaceuticals (MNTA +4%) as analyst Ami Fadi says management's rhetoric indicates approval for generic Copaxone may come in time for 2015 patent expirations. The shares are upgraded to Buy from Neutral (price target to $17 from $13). For a detailed discussion of the MNTA vs. Teva Copaxone story, see SA contributor Jon Crowley's recent article.
http://m.seekingalpha.com/article/1453781-why-momenta-offers-a-unique-opportunity-in-the-pharmaceutical-industry